Quantcast
Last updated on April 25, 2014 at 1:22 EDT

HPV Testing for Cervical Cancer Risk Patients set to Increase

January 23, 2012

LONDON, January 23, 2012 /PRNewswire/ –

Roche sets up co -marketing agreement with private laboratory to support greater
access to HPV testing

In an innovative commercial agreement, leading healthcare company Roche and foremost
private cellular pathology laboratory Unilabs-IHS, are collaborating to help make
state-of-the art testing for signs of cervical cancer more accessible to thousands of
women in London and throughout the UK.

Roche’s leading-edge and fully automated cobas(R) HPV test which runs on the acclaimed
cobas 4800 system, will provide a fast turn-around of cervical smear samples from
potentially thousands of women per year, sent to the London based laboratory from
clinicians from all over the country. The testing at Unilabs-IHS, will not only be
conducted as a follow up to the traditional “Pap” cervical smear method to check ambiguous
results, it will also be used upon request in primary screening for cervical pre cancer,
giving a greater chance to avoid disease progression.

The ultra-high reliability of the cobas HPV test will be of huge benefit for
clinicians and patients alike, due to the test’s unique genotyping that individually
identifies genotypes 16 and 18, the highest risk types associated with the development of
cervical cancer and its precursor lesions, while simultaneously identifying 12 other high
risk HPV types. Such technology provides better risk stratification of patients enabling a
more sensitive and efficient approach to cervical screening.

Dr Glen Dixon, Medical Director of Cytopathology at Unilabs-IHS from Unilabs-IHS said
“We are delighted to have come to this agreement with Roche. Using the cobas HPV test on
the cobas 4800 platform for our HPV testing work load, means that clinicians will not only
have the fastest ever turnaround times, but will also have enhanced and incontrovertible
HPV results, with no need to re-test – and all at no extra cost.”

Paul Eros, Director of Molecular Diagnostics at Roche said: “HPV testing provides
earlier identification of those women at risk of developing cervical cancer. The agreement
that we have struck with Unilabs-IHS for cervical screening with the cobas HPV test, is a
significant step forward towards spreading access to HPV testing at the primary screening
stage. Given the clear benefits of this technology to patients as well as the NHS, we look
forward to seeing the technology’s timely introduction at the primary screening stage,
across the country via the national cervical screening programme – promising a better deal
for women and a more efficient approach to cervical screening.”

About the cobas(R) HPV Test on the cobas 4800 platform
Roche’s cobas HPV Test simultaneously detects 12 high-risk HPV types (HPV types 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) as a pooled result, as well as HPV genotypes 16
and 18 individually. Roche received FDA approval on the cobas(R) HPV Test and in April
2011 and launched the cobas HPV Test in countries that accept CE Mark in 2009. Due to key
features such as the “load and go” facility for reagents, The cobas HPV test is easy and
simple to use with minimal hands-on and maximum walkaway time whilst providing high
throughput capabilities and has the flexibility to meet smaller throughput requirements.
About Human Papillomavirus and Cervical Cancer
Persistent infection with human papillomavirus is the cause of cervical cancer in women,
with HPV being found in 99.7 per cent of cervical cancers worldwide. Of the more than 118
different types of HPV, the cobas(R) HPV Test identifies the 14 high-risk types associated
with the development of cervical cancer and its precursor lesions. HPV types 16 and 18
have been identified as the highest risk genotypes, detected in approximately 70 per cent
of cervical cancers. Nucleic acid (DNA) testing is a sensitive and non-invasive method for
determining the presence of HPV infection. The World Health Organization estimates there
are 470,000 new cases of cervical cancer annually.

About Unilabs
Unilabs UK are a leading supplier of Cellular Pathology Services, Nucleic Acid
Amplification Testing, and Breast Diagnostic services in the United Kingdom.Unilabs UK
provides Cellular Pathology Services and Nucleic Acid Amplification Testing to the private
and public sectors, employing highly specialised consultants backed by high calibre
laboratory and administrative staff. About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with
combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest
biotech company with truly differentiated medicines in oncology, virology, inflammation,
metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based
cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare
strategy aims at providing medicines and diagnostic tools that enable tangible
improvements in the health, quality of life and survival of patients. In 2010, Roche had
over 80,000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group
posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned
member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan.

All trademarks used or mentioned in this release are legally protected.

For more information: http://www.roche.com

SOURCE Roche


Source: PR Newswire